ImmuPharma (LON:IMM) Shares Down 10% - Here's What Happened

Key Points

• ImmuPharma's stock fell by 10% on Monday, closing at GBX 11.25 ($0.15), down from GBX 12.50 ($0.17) the previous day, with a significant increase in trading volume.
• The company's negative return on equity stood at 131.41%, and analysts forecast a loss of GBX -339.0000022 earnings per share for the current fiscal year.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, showing promise for treating Lupus and other related conditions.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price was down 10% on Monday . The company traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.25 ($0.15). Approximately 11,107,625 shares were traded during trading, an increase of 30% from the average daily volume of 8,513,286 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Stock Performance

The firm has a market cap of £56.23 million, a PE ratio of -1,264.38 and a beta of 1.53. The stock's fifty day moving average price is GBX 4.46 and its 200-day moving average price is GBX 3.33.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Sell-side analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.